Gyre Therapeutics annual ebitda
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Gyre Therapeutics EBITDA Growth & History (GYRE)
Gyre Therapeutics's calculated EBITDA was $14.0M for fiscal 2025.
View full Gyre Therapeutics company overviewGyre Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $14.0M | −$3.7M | −21.14% |
| 2024 | 2024-12-31 | $17.7M | $83.9M | — |
| 2023 | 2023-12-31 | −$66.2M | −$76.4M | — |
| 2022 | 2022-12-31 | $10.3M | $97.9M | — |
| 2021 | 2021-12-31 | −$87.6M | −$30.4M | — |
| 2020 | 2020-12-31 | −$57.2M | −$101,000 | — |
| 2019 | 2019-12-31 | −$57.1M | −$23.5M | — |
| 2018 | 2018-12-31 | −$33.7M | −$12.0M | — |
| 2017 | 2017-12-31 | −$21.6M | −$1.6M | — |
| 2016 | 2016-12-31 | −$20.0M | −$6.7M | — |
| 2015 | 2015-12-31 | −$13.3M | −$6.5M | — |
| 2014 | 2014-12-31 | −$6.8M | $2.3M | — |
| 2013 | 2013-12-31 | −$9.1M | −$3.2M | — |
| 2012 | 2012-12-31 | −$5.9M | $1.3M | — |
| 2011 | 2011-12-31 | −$7.3M | −$22.4M | — |
| 2010 | 2010-12-31 | $15.1M | $53.6M | — |
| 2009 | 2009-12-31 | −$38.5M | — | — |
Gyre Therapeutics quarterly ebitda
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$12.9M | −$11.6M | — |
| Q1 2026 | 2026-03-31 | −$8.7M | −$11.5M | — |
| Q4 2025 | 2025-12-31 | $5.2M | $4.1M | +360.48% |
| Q3 2025 | 2025-09-30 | $7.2M | $2.5M | +54.04% |
| Q2 2025 | 2025-06-30 | −$1.2M | −$4.7M | — |
| Q1 2025 | 2025-03-31 | $2.8M | −$5.7M | −66.91% |
| Q4 2024 | 2024-12-31 | $1.1M | $92.5M | — |
| Q3 2024 | 2024-09-30 | $4.7M | −$8.3M | −63.89% |
| Q2 2024 | 2024-06-30 | $3.4M | −$1.9M | −35.21% |
| Q1 2024 | 2024-03-31 | $8.5M | $1.5M | +22.28% |
| Q4 2023 | 2023-12-31 | −$91.3M | −$69.7M | — |
| Q3 2023 | 2023-09-30 | $13.0M | $18.1M | — |
| Q2 2023 | 2023-06-30 | $5.3M | −$46.3M | −89.76% |
| Q1 2023 | 2023-03-31 | $6.9M | $21.5M | — |
| Q4 2022 | 2022-12-31 | −$21.6M | −$1.4M | — |
| Q3 2022 | 2022-09-30 | −$5.1M | $20.0M | — |
| Q2 2022 | 2022-06-30 | $51.6M | $71.5M | — |
| Q1 2022 | 2022-03-31 | −$14.6M | $7.8M | — |
| Q4 2021 | 2021-12-31 | −$20.2M | −$1.4M | — |
| Q3 2021 | 2021-09-30 | −$25.1M | −$9.1M | — |
| Q2 2021 | 2021-06-30 | −$19.9M | −$2.5M | — |
| Q1 2021 | 2021-03-31 | −$22.4M | −$17.4M | — |
| Q4 2020 | 2020-12-31 | −$18.8M | −$4.8M | — |
| Q3 2020 | 2020-09-30 | −$16.1M | −$2.9M | — |
| Q2 2020 | 2020-06-30 | −$17.3M | −$3.0M | — |
| Q1 2020 | 2020-03-31 | −$5.0M | $10.6M | — |
| Q4 2019 | 2019-12-31 | −$14.0M | −$2.3M | — |
| Q3 2019 | 2019-09-30 | −$13.2M | −$4.9M | — |
| Q2 2019 | 2019-06-30 | −$14.3M | −$7.3M | — |
| Q1 2019 | 2019-03-31 | −$15.7M | −$9.0M | — |
| Q4 2018 | 2018-12-31 | −$11.6M | −$5.9M | — |
| Q3 2018 | 2018-09-30 | −$8.3M | −$2.5M | — |
| Q2 2018 | 2018-06-30 | −$7.1M | −$1.2M | — |
| Q1 2018 | 2018-03-31 | −$6.6M | −$2.5M | — |
| Q4 2017 | 2017-12-31 | −$5.8M | −$630,000 | — |
| Q3 2017 | 2017-09-30 | −$5.8M | −$233,000 | — |
| Q2 2017 | 2017-06-30 | −$5.9M | −$1.1M | — |
| Q1 2017 | 2017-03-31 | −$4.1M | $344,000 | — |
| Q4 2016 | 2016-12-31 | −$5.2M | −$579,000 | — |
| Q3 2016 | 2016-09-30 | −$5.6M | −$1.8M | — |
| Q2 2016 | 2016-06-30 | −$4.8M | −$2.7M | — |
| Q1 2016 | 2016-03-31 | −$4.5M | −$1.5M | — |
| Q4 2015 | 2015-12-31 | −$4.6M | −$18.8M | — |
| Q3 2015 | 2015-09-30 | −$3.8M | −$2.6M | — |
| Q2 2015 | 2015-06-30 | −$2.1M | $6.1M | — |
| Q1 2015 | 2015-03-31 | −$2.9M | $8.8M | — |
| Q4 2014 | 2014-12-31 | $14.2M | −$10.0M | −41.41% |
| Q3 2014 | 2014-09-30 | −$1.2M | $11.8M | — |
| Q2 2014 | 2014-06-30 | −$8.2M | $4.1M | — |
| Q1 2014 | 2014-03-31 | −$11.7M | −$3.6M | — |
| Q4 2013 | 2013-12-31 | $24.2M | $40.1M | — |
| Q3 2013 | 2013-09-30 | −$13.0M | −$5.5M | — |
| Q2 2013 | 2013-06-30 | −$12.3M | −$27.2M | — |
| Q1 2013 | 2013-03-31 | −$8.1M | −$10.7M | — |
| Q4 2012 | 2012-12-31 | −$15.9M | −$6.3M | — |
| Q3 2012 | 2012-09-30 | −$7.5M | $1.2M | — |
| Q2 2012 | 2012-06-30 | $14.9M | $16.8M | — |
| Q1 2012 | 2012-03-31 | $2.6M | −$10.3M | −79.71% |
| Q4 2011 | 2011-12-31 | −$9.5M | −$12.5M | — |
| Q3 2011 | 2011-09-30 | −$8.7M | — | — |
| Q2 2011 | 2011-06-30 | −$1.9M | — | — |
| Q1 2011 | 2011-03-31 | $12.9M | — | — |
| Q3 2010 | 2010-09-30 | $2.9M | — | — |
Gyre Therapeutics ebitda trends
Over the last five reported fiscal years, Gyre Therapeutics's ebitda increased from −$57.2M to $14.0M, a change of $71.2M. The latest reported quarter, Q2 2026, shows −$12.9M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gyre Therapeutics filings at SEC.gov ↗